Polidocanol

A naturally-occurring sterol and biosynthetic precursor of several animal, fungal, and protozoan steroids, including cholesterol and ergosterol.

A naturally-occurring sterol and biosynthetic precursor of several animal, fungal, and protozoan steroids, including cholesterol and ergosterol.

A naturally-occurring sterol and biosynthetic precursor of several animal, fungal, and protozoan steroids, including cholesterol and ergosterol.

Lipoprotein Lipase (LPL) is majorly secreted by myocytes and adipocytes in humans and is crucial for triglyceride homeostatis. Mutations in the catalytic domain of LPL impairs its interaction with glycosylphosphatidylinositol anchored high density

Lipoprotein Lipase (LPL) is majorly secreted by myocytes and adipocytes in humans and is crucial for triglyceride homeostatis. Mutations in the catalytic domain of LPL impairs its interaction with glycosylphosphatidylinositol anchored high density

LPA2 antagonist 2 (H2L 5226501) is a selective LPA 2 antagonist with an IC 50 of 28.3 nM and a K i of 21.1 nM. LPA2 antagonist 2 is &gt:480-fold more selective than LPA 3 ( IC 50 of 13.85 μM)In VitroLysophosphatidic acid (LPA) is a phospholipid

LPA2 antagonist 2 (H2L 5226501) is a selective LPA 2 antagonist with an IC 50 of 28.3 nM and a K i of 21.1 nM. LPA2 antagonist 2 is &gt:480-fold more selective than LPA 3 ( IC 50 of 13.85 μM)In VitroLysophosphatidic acid (LPA) is a phospholipid

LPA2 antagonist 2 (H2L 5226501) is a selective LPA 2 antagonist with an IC 50 of 28.3 nM and a K i of 21.1 nM. LPA2 antagonist 2 is &gt:480-fold more selective than LPA 3 ( IC 50 of 13.85 μM)In VitroLysophosphatidic acid (LPA) is a phospholipid

LPA2 antagonist 2 (H2L 5226501) is a selective LPA 2 antagonist with an IC 50 of 28.3 nM and a K i of 21.1 nM. LPA2 antagonist 2 is &gt:480-fold more selective than LPA 3 ( IC 50 of 13.85 μM)In VitroLysophosphatidic acid (LPA) is a phospholipid

General description The protein encoded by this gene is a cytosolic protein which contains a phosphotyrosine binding (PTD) domain. The PTD domain has been found to interact with the cytoplasmic tail of the LDL receptor.

Ongericimab (anti-PCSK9) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab (anti-PCSK9) has lipid-lowering efficacy.

Ongericimab (anti-PCSK9) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab (anti-PCSK9) has lipid-lowering efficacy.